A nephrology CRO is a Contract Research Organization that designs and conducts preclinical studies focused specifically on kidney disease, as opposed to a generalist CRO that covers many therapeutic areas with kidney testing as a secondary offering. NEPHRIX Biosolutions is built  around renal disease models, combining in vitro systems and in vivo studies for Chronic Kidney Disease (CKD), Acute Kidney Injury (AKI), and Diabetic Kidney Disease (DKD).

Some CROs approach kidney disease as a downstream complication of metabolic disorders like diabetes or obesity, and their renal models are secondary to a broader cardiometabolic platform.

NEPHRIX Biosolutions runs a broad panel of validated in vivo kidney disease models, including:

• Acute Kidney Injury (AKI): ischemia-reperfusion injury, available in three variants – Unilateral Ischemia Reperfusion Injury (uIRI), Uninephrectomy + Ischemia Reperfusion Injury (Ux/IRI), and Bilateral Ischemia Reperfusion Injury (bIRI) – plus cisplatin-induced nephrotoxicity and sepsis-induced AKI
• Chronic Kidney Disease (CKD): unilateral ureteral obstruction (UUO), adenine-induced CKD, 5/6 nephrectomy
• Diabetic Kidney Disease (DKD): streptozotocin (STZ) induced diabetic nephropathy, db/db model
• Other renal pathologies: IgA nephropathy, focal segmental glomerulosclerosis (FSGS), hypertensive nephropathy.

NEPHRIX Biosolutions pairs in vivo studies with disease relevant in vitro systems using primary and immortalized renal cell lines, enabling early mechanism-of-action and toxicity screening before moving into animal models, reducing risk and cost ahead of in vivo confirmation.

SStudies are supported by a validated biomarker panel including KIM-1, NGAL, GFR, BUN, creatinine, α-SMA, and TGF-β1, alongside quantitative histopathology, to characterize both functional and structural kidney damage.

Studies are supported by a validated biomarker panel including KIM-1, NGAL, GFR, BUN, creatinine, α-SMA, and TGF-β1, alongside quantitative histopathology, to characterize both functional and structural kidney damage.

Yes. NEPHRIX Biosolutions works seamlessly with European sponsors under standard EU regulatory and logistics frameworks, while also supporting US-based biotech and pharma teams with FDA-aligned study design, regulatory-ready data packages, and streamlined cross-border project management-all from facilities integrated with Paul Sabatier University’s imaging and molecular platforms.